Compare FOR & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOR | AMLX |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2007 | 2021 |
| Metric | FOR | AMLX |
|---|---|---|
| Price | $25.06 | $14.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $31.75 | $19.56 |
| AVG Volume (30 Days) | 118.1K | ★ 820.0K |
| Earning Date | 04-21-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $1,662,400,000.00 | $380,786,000.00 |
| Revenue This Year | $0.52 | N/A |
| Revenue Next Year | $7.72 | N/A |
| P/E Ratio | $83.10 | ★ N/A |
| Revenue Growth | 10.14 | ★ 1612.94 |
| 52 Week Low | $18.00 | $3.11 |
| 52 Week High | $30.74 | $17.49 |
| Indicator | FOR | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 31.34 | 49.03 |
| Support Level | $24.05 | $13.28 |
| Resistance Level | $26.00 | $15.41 |
| Average True Range (ATR) | 0.87 | 0.96 |
| MACD | -0.47 | -0.04 |
| Stochastic Oscillator | 13.78 | 34.13 |
Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. the company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.